These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36397167)

  • 1. Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study.
    Chyrchel B; Kruszelnicka O; Surdacki A
    Cardiovasc Diabetol; 2022 Nov; 21(1):249. PubMed ID: 36397167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
    Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
    Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
    Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
    Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
    Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
    Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
    J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
    Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
    Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
    Hauguel-Moreau M; Boccara F; Boyd A; Salem JE; Brugier D; Curjol A; Hulot JS; Kerneis M; Galier S; Cohen A; Montalescot G; Collet JP; Silvain J
    Eur Heart J; 2017 Jun; 38(21):1676-1686. PubMed ID: 28065907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
    Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
    J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
    Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
    JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
    Gaglia MA; Lipinski MJ; Lhermusier T; Steinvil A; Kiramijyan S; Pokharel S; Torguson R; Angiolillo DJ; Wallentin L; Storey RF; Waksman R
    Am J Cardiol; 2017 Apr; 119(8):1135-1140. PubMed ID: 28202132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
    Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J
    Platelets; 2019; 30(3):341-347. PubMed ID: 29521570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.